Advertisement

Breast Cancer Research and Treatment

, Volume 165, Issue 3, pp 677–686 | Cite as

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

  • Shirley M. BluethmannEmail author
  • Catherine M. Alfano
  • Jonathan D. Clapp
  • George Luta
  • Brent J. Small
  • Arti Hurria
  • Harvey J. Cohen
  • Steven Sugarman
  • Hyman B. Muss
  • Claudine Isaacs
  • Jeanne S. Mandelblatt
Epidemiology

Abstract

Purpose

To investigate the effects of cognitive function on discontinuation of hormonal therapy in breast cancer survivors ages 65+ (“older”).

Methods

Older breast cancer survivors with invasive, non-metastatic disease, and no reported cognitive difficulties were recruited from 78 Alliance sites between 2004 and 2011. Eligible survivors (n = 1280) completed baseline interviews; follow-up was conducted annually for up to 7 years. Survivors with estrogen-receptor-positive (ER+) cancers who initiated hormonal therapy (n = 990) were included. Self-reported cognitive function was measured using the EORTC-QLQ30 scale; a difference of eight points on the 0–100 scale was considered clinically significant. Based on varying rates of discontinuation over time, discontinuation was evaluated separately for three time periods: early (<1 year); midpoint (1–3 years); and late discontinuation (>3–5 years). Cox models for each time period were used to evaluate the effects of cognition immediately preceding discontinuation, controlling for age, chemotherapy, and other covariates.

Results

Survivors were 65–91 years old (mean 72.6 years), and 79% had stages 1 or 2A disease. Overall, 43% discontinued hormonal therapy before 5 years. Survivors who reported lower cognitive function in the period before discontinuation had greater hazards of discontinuing therapy at the treatment midpoint (HR 1.22 per 8-point difference, CI 1.09–1.40, p < 0.001), considering covariates, but cognition was not related to discontinuation in the other periods.

Conclusions

Self-reported cognitive problems were a significant risk factor for discontinuation of hormonal therapy 1–3 years post-initiation. Additional research is needed on the temporality of cognitive effects and hormonal therapy to support survivorship care needs of older survivors.

Keywords

Survivorship Adjuvant therapy Aging Cognition Cognitive function 

Notes

Acknowledgements

Earlier versions of this research were presented by Dr. Bluethmann at the International Association of Gerontology and Geriatrics World Congress, July 23–27, 2017, San Francisco, CA.

Funding

This research was conducted under Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B) Protocol #369901. The research infrastructure was supported by UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant), U10CA031946, U10C0A33601, U10CA032291, U10CA047559, U10CA047577, U10CA077597, U10CA077651, U10CA180791, U10CA180857, U10CA180867, U10CA180838, and U10CA84131 to the Alliance. The research was also supported, in part, by NCI Grants R35CA197289, R01CA129769, R01CA124924, and K05CA96940 to JSM; and the Biostatistics and Bioinformatics Shared Resources at Georgetown-Lombardi Comprehensive Cancer Center funded by the National Cancer Institute at the National Institutes of Health under grant P30CA051008. Dr. Bluethmann was funded through the Cancer Prevention Fellowship at the National Cancer Institute at the time this report was prepared. Earlier portions of the research were also funded in part by a grant to support patient accrual from Amgen Pharmaceuticals to the CALGB Foundation. The content of this manuscript is solely the responsibility of the authors and does not represent the official views of the National Cancer Institute at the National Institutes of Health or the Alliance for Clinical Trials in Oncology.

Compliance with ethical standards

Conflict of interest

Dr. Isaacs received remuneration and funding from Astra Zeneca, Pfizer, and Novartis. She is also a consultant/advisor for Astra Zeneca, Novartis, and Nanostring Technologies. Dr. Hurria is a consultant for Pierian Bioscience and Boehringer Ingelheim. She has also received funded from Celgene, Novartis, and GlaxoSmithKline. All other authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study. The protocol met Health Insurance Portability and Accountability Act standards and was approved by CALGB, the National Cancer Institute, and the institutional review boards at all sites. Each participant signed an IRB-approved, protocol-specific consent form in accordance with federal and institutional guidelines.

References

  1. 1.
    Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9CrossRefGoogle Scholar
  2. 2.
    Chlebowski RT, Kim J, Haque R (2014) Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res 7:378–387CrossRefGoogle Scholar
  3. 3.
    Gray RG, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31:5CrossRefGoogle Scholar
  4. 4.
    Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group, Buzdar A, Howell A et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643CrossRefGoogle Scholar
  5. 5.
    Murphy CC, Bartholomew LK, Carpentier MY et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134:459–478CrossRefGoogle Scholar
  6. 6.
    Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796CrossRefGoogle Scholar
  7. 7.
    Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269CrossRefGoogle Scholar
  8. 8.
    Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128CrossRefGoogle Scholar
  9. 9.
    Hershman DL (2013) Disparities and challenges in adherence to oral antineoplastic agentsGoogle Scholar
  10. 10.
    Bluethmann SM, Murphy CC, Tiro JA et al (2017) Deconstructing decisions to initiate, maintain, or discontinue adjuvant endocrine therapy in breast cancer survivors: a mixed-methods study. Oncol Nurs Forum 44(3):E101–E110CrossRefGoogle Scholar
  11. 11.
    Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145:525–534CrossRefGoogle Scholar
  12. 12.
    Lange M, Rigal O, Clarisse B et al (2014) Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists. Cancer Treat Rev 40:810–817CrossRefGoogle Scholar
  13. 13.
    Karuturi M, Wong ML, Hsu T et al (2016) Understanding cognition in older patients with cancer. J Geriatr Oncol 7:258–269CrossRefGoogle Scholar
  14. 14.
    Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834CrossRefGoogle Scholar
  15. 15.
    Agrawal K, Onami S, Mortimer JE et al (2010) Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 67:209–214CrossRefGoogle Scholar
  16. 16.
    Ganz PA, Kwan L, Castellon SA et al (2013) Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst 105:791–801CrossRefGoogle Scholar
  17. 17.
    Bellury L, Ellington L, Beck SL et al (2013) Older breast cancer survivors: can interaction analyses identify vulnerable subgroups? A report from the American Cancer Society Studies of Cancer Survivors. 40Google Scholar
  18. 18.
    Bailey M, Wang AC, Hao J et al (2011) Interactive effects of age and estrogen on cortical neurons: implications for cognitive aging. Neuroscience 191:148–158CrossRefGoogle Scholar
  19. 19.
    Phillips K, Aldridge J, Ribi K et al (2011) Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 126:221–226CrossRefGoogle Scholar
  20. 20.
    Bender CM, Merriman JD, Gentry AL et al (2015) Patterns of change in cognitive function with anastrozole therapy. Cancer 121:2627–2636CrossRefGoogle Scholar
  21. 21.
    Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomark Prev 25:1029–1036CrossRefGoogle Scholar
  22. 22.
    Mandelblatt JS, Sheppard VB, Hurria A et al (2010) Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol 28:3146–3153CrossRefGoogle Scholar
  23. 23.
    Mandelblatt JS, Faul LA, Luta G et al (2012) Patient and physician decision styles and breast cancer chemotherapy use in older women: cancer and leukemia group B protocol 369901. J Clin Oncol 30:2609–2614CrossRefGoogle Scholar
  24. 24.
    Davis PB, Morris JC, Grant E (1990) Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. J Am Geriatr Soc 38:129–135CrossRefGoogle Scholar
  25. 25.
    Kawas C, Karagiozis H, Resau L et al (1995) Reliability of the blessed telephone information-memory-concentration test. J Geriatr Psychiatry Neurol 8:238–242CrossRefGoogle Scholar
  26. 26.
    Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefGoogle Scholar
  27. 27.
    Lash TL, Fox MP, Westrup JL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220CrossRefGoogle Scholar
  28. 28.
    Searle SD, Mitnitski A, Gahbauer EA et al (2008) A standard procedure for creating a frailty index. BMC Geriatr 8:24CrossRefGoogle Scholar
  29. 29.
    Rockwood K, Mitnitski A, Song X et al (2006) Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc 54:975–979CrossRefGoogle Scholar
  30. 30.
    Sheppard VB, Faul LA, Luta G et al (2014) Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol 32:2318–2327CrossRefGoogle Scholar
  31. 31.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  32. 32.
    Bender CM, Sereika SM, Brufsky AM et al (2007) Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14:995–998CrossRefGoogle Scholar
  33. 33.
    Cox D (1972) Regression Models and Life-Tables. Journal of the Royal Statistical Society. Series B (Methodological) 34:187–220CrossRefGoogle Scholar
  34. 34.
    He W, Fang F, Varnum C et al (2015) Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol 33:2262–2269CrossRefGoogle Scholar
  35. 35.
    Mayer EL, Burstein HJ (2015) Adjuvant endocrine therapy for postmenopausal women: type and duration. Breast 24:S126–S128CrossRefGoogle Scholar
  36. 36.
    Neugut AI, Hillyer GC, Kushi LH et al (2012) The breast cancer quality of care study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J 18:203–213CrossRefGoogle Scholar
  37. 37.
    Neugut AI, Zhong X, Wright JD et al (2016) Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol 2(10):1326–1332CrossRefGoogle Scholar
  38. 38.
    Hershman DL, Kushi LH, Hillyer GC et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157:133–143CrossRefGoogle Scholar
  39. 39.
    Zwart W, Terra H, Linn SC et al (2015) Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on? Nat Rev Clin Oncol 12:597–606CrossRefGoogle Scholar
  40. 40.
    Ganz PA (2016) Understanding the impact of breast cancer adjuvant endocrine therapy on cognitive function: a work in progress. Br J Cancer 114:953–955CrossRefGoogle Scholar
  41. 41.
    Daniel JM (2013) Estrogens, estrogen receptors, and female cognitive aging: the impact of timing. Horm Behav 63:231–237CrossRefGoogle Scholar
  42. 42.
    Kesler SR, Kent JS, O’Hara R (2011) Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 68:1447–1453CrossRefGoogle Scholar
  43. 43.
    Wefel JS, Vardy J, Ahles T et al (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708CrossRefGoogle Scholar
  44. 44.
    Hurria A, Patel SK, Mortimer J et al (2014) The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer 14:132–140CrossRefGoogle Scholar
  45. 45.
    Kool M, Fontein D, Kranenbarg EM et al (2015) Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients. Breast 24:224–229CrossRefGoogle Scholar
  46. 46.
    Mandelblatt JS, Hurria A, McDonald BC et al (2013) Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? Semin Oncol 40:709–725CrossRefGoogle Scholar
  47. 47.
    Mandelblatt JS, Jacobsen PB, Ahles T (2014) Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 32:2617–2626CrossRefGoogle Scholar
  48. 48.
    Cohen HJ (2007) The cancer aging interface: a research agenda. J Clin Oncol 25:1945–1948CrossRefGoogle Scholar
  49. 49.
    Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107:167–180CrossRefGoogle Scholar
  50. 50.
    Fayers P, Aaronson N, Bjordal K et al (2015) The EORTC QLQ-C30 scoring manual. 2001. European Organisation for Research and Treatment of Cancer, Brussels, p 3Google Scholar
  51. 51.
    Ercoli L, Petersen L, Hunter A et al (2015) Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psycho Oncol 24:1360–1367CrossRefGoogle Scholar
  52. 52.
    Von Ah D, Carpenter JS, Saykin A et al (2012) Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 135:799–809CrossRefGoogle Scholar
  53. 53.
    Mustian KM, Sprod LK, Janelsins M et al (2012) Exercise recommendations for cancer-related fatigue, cognitive impairment, sleep problems, depression, pain, anxiety, and physical dysfunction: a review. Oncol Hematol Rev 8:81–88PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Shirley M. Bluethmann
    • 1
    Email author
  • Catherine M. Alfano
    • 2
  • Jonathan D. Clapp
    • 3
  • George Luta
    • 4
  • Brent J. Small
    • 5
  • Arti Hurria
    • 6
  • Harvey J. Cohen
    • 7
  • Steven Sugarman
    • 8
  • Hyman B. Muss
    • 9
  • Claudine Isaacs
    • 10
  • Jeanne S. Mandelblatt
    • 3
    • 10
  1. 1.Department of Public Health Sciences, College of MedicineThe Pennsylvania State UniversityHersheyUSA
  2. 2.American Cancer Society, Inc.WashingtonUSA
  3. 3.Department of OncologyGeorgetown University Medical Center and Georgetown-Lombardi Comprehensive Cancer CenterWashingtonUSA
  4. 4.Department of Biostatistics, Bioinformatics and BiomathematicsGeorgetown University Medical Center and Georgetown-Lombardi Comprehensive Cancer CenterWashingtonUSA
  5. 5.School of Aging StudiesUniversity of South Florida, Moffitt Cancer CenterTampaUSA
  6. 6.Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarteUSA
  7. 7.Department of Medicine and Center for the Study of Aging and Human DevelopmentDuke UniversityDurhamUSA
  8. 8.Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  9. 9.Department of Medicine, UNC-Chapel Hill School of MedicineUniversity of North CarolinaChapel HillUSA
  10. 10.Department of MedicineGeorgetown University Medical Center and Georgetown-Lombardi Comprehensive Cancer CenterWashingtonUSA

Personalised recommendations